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Malaria remains a major global health problem. Emerging resis-
tance to existing antimalarial drugs drives the search for new
antimalarials, and protein translation is a promising pathway to
target. Here we explore the potential of the aminoacyl-tRNA
synthetase (ARS) family as a source of antimalarial drug targets.
First, a battery of known and novel ARS inhibitors was tested
against Plasmodium falciparum cultures, and their activities were
compared. Borrelidin, a natural inhibitor of threonyl-tRNA synthe-
tase (ThrRS), stands out for its potent antimalarial effect. However,
it also inhibits human ThrRS and is highly toxic to human cells. To
circumvent this problem, we tested a library of bioengineered and
semisynthetic borrelidin analogs for their antimalarial activity and
toxicity. We found that some analogs effectively lose their toxicity
against human cells while retaining a potent antiparasitic activity
both in vitro and in vivo and cleared malaria from Plasmodium
yoelii-infected mice, resulting in 100%mice survival rates. Our work
identifies borrelidin analogs as potent, selective, and unexplored
scaffolds that efficiently clear malaria both in vitro and in vivo.
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With ∼200 million clinical cases and more than 600,000 at-tributed deaths per year (World Health Organization
Malaria Report 2013), malaria is one of the most severe in-
fectious diseases for which there is no effective vaccine. Most
deaths by malaria are caused by Plasmodium falciparum, one of the
five distinct Plasmodium species that infect humans, whereas the
high morbidity of Plasmodium vivax, which can cause dormant liver
stage infections, also contributes to the enormous economic burden
of the disease. Because malaria parasites contain an essential or-
ganelle of bacterial origin, the apicoplast, numerous antibacterials
kill malaria parasites (1–4) and are commonly used in malaria
prophylaxis or as components of multiple drug therapies (5, 6).
However, the emergence of multiresistant parasites compromises
the efficacy of many existing chemotherapies, leading to a growing
urgency for the search of new antimalarials (7–11).
The protein synthesis machinery is an excellent target for the
development of new anti-infectives. Indeed, commonly used
antimalarial compounds such as doxycycline inhibit Plasmodium
ribosomal function. Among the less exploited enzymes of the
translation machinery is the family of aminoacyl-tRNA synthe-
tases (ARS). These ancestral enzymes catalyze the correct at-
tachment of amino acids to their cognate tRNAs and thus are
responsible for the correct establishment of the genetic code.
An important example of the clinical application of an ARS
inhibitor is provided by the antibiotic mupirocin (pseudomonic
acid; marketed as Bactroban, GlaxoSmithKline), which selec-
tively inhibits bacterial isoleucyl-tRNA synthetase without in-
hibiting its human homolog. Although proven antibacterial drug
targets (12–15), these enzymes have only recently been high-
lighted as antimalarial drug targets (16–18).
A major limitation of most antimalarial drugs is their inability
to affect the liver stages of malaria, including P. vivax and P. ovale
hypnozoites. The essential role of ARS in both liver and blood
stages of malaria represents an additional advantage for their use
as antimalarial targets (19). Recently, high-throughput pheno-
typic screens have shown plasmodial ARS to be druggable targets
that can be selectively inhibited (16). In this latter work, clado-
sporin, a fungal secondary metabolite, was found to target the
cytosolic lysyl-tRNA synthetase (LysRS) of the malaria parasite.
Antimalarial ARS-directed drug design has also been applied
satisfactorily against apicoplastic and cytosolic isoleucyl-tRNA
synthetase (IleRS) (17) and apicoplastic LysRS (18). However, all
previously identified antimalarial drugs targeting ARS either
lacked potency (18) did not show in vivo antimalarial activity (17)
or showed poor oral bioavailability (16).
Significance
Malaria remains one of the main health threats in the de-
veloping world, with staggering social and economic costs.
Resistance to artemisins, the main pharmacological tool cur-
rently available against malaria, has been widely reported.
Borrelidin, a natural compound that inhibits threonyl-tRNA
synthetase, has long been studied for its antibacterial and an-
tiparasitic properties, but undesirable toxic effects prevented its
further clinical development. Here we present a group of bor-
relidin derivatives that retain their ability to inhibit Plasmodium
threonyl-tRNA synthetase but not its human homolog. Fur-
thermore, we demonstrate, for the first time to our knowledge,
that these compounds are capable of effectively clearing a
Plasmodium infection in animals, curing malaria with a potency
equivalent to reference drugs such as chloroquine.
Author contributions: E.M.N., M.R., A.C., and L.R.d.P. designed research; E.M.N., N.C., A.T.,
P.M.-G., I.G.A., J.M.B., A.C.M., C.S.F., and S.V. performed research; B.W., S.M., and A.C.
contributed new reagents/analytic tools; E.M.N., N.C., and L.R.d.P. analyzed data; and
E.M.N. and L.R.d.P. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission. S.A.M. is a guest editor invited by the Editorial
Board.
1Present address: Computer Science and Artificial Intelligence Laboratory, Massachusetts
Institute of Technology, Cambridge, MA 02139.
2Present address: John Innes Centre, Norwich NR4 7UH, United Kingdom.
3Present address: Barcelona Centre for International Health Research (CRESIB, Hospital
Clínic-Universitat de Barcelona), 08036 Barcelona, Spain.
4To whom correspondence should be addressed. Email: lluis.ribas@irbbarcelona.org.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1405994111/-/DCSupplemental.
E5508–E5517 | PNAS | Published online December 8, 2014 www.pnas.org/cgi/doi/10.1073/pnas.1405994111
To further explore plasmodial ARS as antimalarial drug targets
we tested a battery of known ARS inhibitors against P. falciparum
cell cultures. Among these, we found that borrelidin exhibits
excellent antimalarial activity, as previously reported (20–22).
Borrelidin is a noncompetitive inhibitor of both bacterial and
eukaryotic threonyl-tRNA synthetases (ThrRS) (23) and exhibits
antiangiogenic (24–26), antimalarial (21, 22), and antimicrobial
(27) properties. The antimalarial activity of borrelidin is thought
to arise from inhibition of ThrRS, which in Plasmodium, is
present as a single enzyme dually targeted to cytosol and api-
coplast (28). However, its high cytotoxicity in humans limits its
use (29). Moreover, a borrelidin analog was recently described
with an antimalarial activity 10-fold lower than borrelidin, but
with a cytotoxic effect against human cells 70-fold lower than the
parent compound (30). These reports highlight the interest in
borrelidin analogs and confirm the potential that analogs may
hold for the discovery of compounds with in vivo activity.
We now tested a series of borrelidin analogs for antimalarial
activity both in vitro and in vivo and for its cytotoxicity in human
cells (Fig. 1). Our results show that several analogs possess higher
selectivity than borrelidin and that specific modifications of the
borrelidin scaffold can lead to increased selectivity without losing
antimalarial activity. Importantly, two of these compounds, BC196
and BC220, efficiently clear the malarial infection in P. yoelii-
infected mice, leading to 100% mice survival.
Results
Screening of Known ARS Inhibitors on P. falciparum. We first
screened a battery of known ARS inhibitors against in vitro
cultures of P. falciparum 3D7 (Table 1). The collection of
inhibitors included (i) analogs of the native ligands or reaction
intermediates (mechanism-based inhibitors); (ii) natural product
inhibitors and their derivatives; and (iii) novel scaffolds targeting
ARS. For each compound, IC50 values were computed both at 48
and 96 h to distinguish between apicoplastic and cytosolic ARS
inhibition. It has been described that the inhibition of apicoplast
maintenance or replication causes a phenotype known as “delayed
death” (31), in which the parasites do not show growth inhibition
during the first asexual cycle of drug treatment (48 h) but die in the
second asexual cycle (96 h) even if the drug is removed after the first
cycle (32). Therefore, we used this phenotype to distinguish be-
tween apicoplastic and cytosolic ARS inhibition.
Our results show that most analogs of the native ligands or
reaction intermediate were active against plasmodial ARS in the
nanomolar range (Table 1). Their similar IC50 values at both 48
and 96 h suggest that these compounds inhibit cytosolic ARS.
Natural product ARS inhibitors were also screened for antima-
larial activity (Table 1). Among these, mupirocin was relatively
inactive at 48 h [IC50 (48 h) = 257 μM], but active in the
nanomolar range during the second asexual cycle [IC50 (96 h) =
93 nM]. This observation is in agreement with previous results
(17) and consistent with its high selectivity toward bacterial-type
enzymes (33, 34), such as the apicoplast-targeted isoleucyl-tRNA
synthetase (IleRS-2). This phenomenon was observed even
when mupirocin was removed from the culture after the first
cycle of incubation. Cispentacin, a proline analog that inhibits
prolyl-tRNA synthetase, was found to be a weak inhibitor of
Plasmodium cultures even though it was previously shown to ef-
fectively protect against systemic Candida albicans and Crypto-
coccus neoformans infections (35). This discrepancy could be due
to the fact that, in fungi, cispentacin accumulates at high in-
tracellular levels through an active transport mechanism (36)
that might be missing in Plasmodium. The results for another
natural product, borrelidin, are described below.
We also show that benzoxaborols have antimalarial activity, in
agreement with recently published results (37). Benzoxaborols,
such as the well-described AN2690 (38, 39), specifically inhibit the
leucyl-tRNA synthetase (LeuRS) editing site by forming a co-
valent bond with the terminal adenosine (A76) of the tRNALeu,
thus trapping the tRNALeu in the editing active site and causing
the death of the pathogen. AN2729 (Anacor Pharmaceuticals)
is another member of these novel boron-containing drugs that
presumably inhibits the editing domain of LeuRS (38, 39).
We investigated the effect of AN2729 on parasite growth and
showed that it is capable of inhibiting P. falciparum cultures at
low micromolar concentrations at 48 h (Table 1), indicating
that boron-based compounds can potentially be used as anti-
malarial drugs.
Borrelidin as an Antimalarial Scaffold. The most potent antimalarial
activity was shown by borrelidin, a potent macrolide known to in-
hibit mammalian, bacterial, and protozoan threonyl-tRNA synthe-
tases (ThrRS) (21, 22, 27, 30, 40). With an IC50 of 0.97 nM,
borrelidin is a more potent antimalarial compound than artemether,
artesunate, or chloroquine (21, 22). Its activity is thought to arise
from inhibition of ThrRS (41). Previous reports have shown that
borrelidin is a noncompetitive inhibitor of ThrRS with respect to
threonine and inhibits the amino acid activation step (23).
Threonyl-tRNA Synthetase Is the Target of Borrelidin in P. falciparum.
Genetic selection of Escherichia coli borrelidin-resistant mutants
showed that borrelidin binds to a hydrophobic region proximal to
the zinc at the active site of ThrRS (23). Indeed, the interaction
between the two molecules relies on a complex network of hy-
drophobic and polar interactions. The fact that other ARSs do
not have a similar cavity in their active site may explain why
borrelidin only inhibits ThrRS and not any other ARS.
To determine whether the decrease in parasitemia caused by
borrelidin is due to the inhibition of plasmodial ThrRS, we first
Fig. 1. Antimalarial drug design strategy and pipeline used for identifying
potent and selective ARS inhibitors.
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performed multiple sequence alignments of ThrRS sequences
and verified that the cluster of amino acids binding borrelidin
in E. coli ThrRS is also conserved in P. falciparum ThrRS
(Fig. S1A). We then confirmed that the aminoacylation activity
of P. falciparum ThrRS is indeed inhibited by borrelidin using in
vitro aminoacylation assays with and without borrelidin (Fig. S1B).
Table 1. Inhibitory activity of known ARS inhibitors tested on P. falciparum cultures
CIDIeneGtegraTrotibihnIerutcurtS 50 (48 h) IC50 (96 h) Fold 96/48 h
Native ligand analogs
Glu-SA Glutamyl-tRNA 
synthetase
PF13_0257/
MAL13P1.281
372.2 nM 463.5 nM 1
Gln-SA Glutaminyl-tRNA 
synthetase
PF13_0170 172.4 nM 150.3 nM 1
Asn-SA Asparaginyl-tRNA 
synthetase
PFB0525w/PFE0475w 88.3 nM 73.4 nM 1
Tyr- SA Tyrosyl-tRNA 
synthetase
MAL8P1.125/
PF11_0181
98.5 nM 84.6 nM 1
Ser-SA Seryl-tRNA 
synthetase
PF07_0073/PFL0770w 39.5 nM 16.9 nM 2
Thialysine Lysyl-tRNA 
synthetase
PF13_0262/PF14_0166 484.8 µM 154.3 µM 3
Mupirocin Isoleucyl-tRNA 
synthetase
PF13_0179/PFL1210w 257.0 µM 93.0 nM 2,763
Borrelidin Threonine-tRNA 
synthetase
PF11_0270 1.24 nM 0.97 nM 1
Cispentacin Prolyl-tRNA 
synthetase
PFL0670c/PFI1240c 573.4 µM 462.8 µM 1
AN2729* Leucyl-tRNA 
synthetase
PFF1095w/PF08_0011 1.03 µM 0.68 µM 2
Natural product inhibitors
Novel scaffolds
*Structure of benzoxaborols corresponds to AN2690.
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Borrelidin Analogs Show Higher Selectivity and Lower Cytotoxicity.
Previous results, in addition to those presented in this study, point
to borrelidin as a potential antimalarial agent (IC50 = 0.97 nM).
However, borrelidin also causes human cell toxicity at low con-
centrations (IC50 = 345 nM), presumably due to inhibition of
human ThrRS (Table 2). Therefore, we decided to screen a li-
brary of borrelidin analogs (Fig. 2) to search for more potent and
selective antimalarial compounds. These analogs include compounds
generated by biosynthetic engineering (24), semisynthesis (42) and
a combination of these methods.
We found that 13 of the analogs tested are active in vitro,
although with reduced potency compared with borrelidin (Table
2 and Table S1). For some of the compounds, the decrease in
potency was only moderate (less than fivefold). Importantly,
most of these analogs also appeared to be less cytotoxic than
borrelidin (Fig. 3). For instance, BC195 displays a 16,000-fold
difference in inhibitory activity when tested on P. falciparum
compared with human cells, whereas the difference for borrelidin
was only 355-fold. Overall, these results suggest that some
borrelidin analogs are up to 50 times more selective than
borrelidin (Fig. 3 and Table 2).
Borrelidin Analogs Clear Malaria in P. yoelii-Infected Mice. Among
the 13 borrelidin derivatives that presented antimalarial activity
at 100 nM, we selected the five most selective compounds (based
on IC50 values) for in vivo studies with P. yoelii-infected mice
(BC194, BC195, BC196, BC220, and BC240). Each compound
was tested at two different concentrations: 0.25 (the effective dose
of borrelidin) and 6 mg/kg per day (the effective dose of chloro-
quine) (Table 3). For each compound and dose, the average par-
asitemia was measured, and the survival time was monitored for up
to 20 d after drug treatment (Fig. 4B).
Our results show that two of the five compounds tested, BC196
and BC220, yield 100% survival at 6 mg/kg per day (Table 3). The
most promising compound, BC220, completely clears the para-
sitemia at 6 mg/kg per day using the 4-d suppresive test (Materials
and Methods), which is comparable to parasite clearance by
chloroquine. Indeed, this compound already induces 80% mice
survival and a very good suppression of parasitemia at 0.25 mg/kg
Table 2. In vitro inhibitory activities of borrelidin analogs both
in P. falciparum cultures and human HEK293 cells
Compound
IC50
48 h (nM)
IC50
96 h (nM)
IC50 72 h
(μM except
where noted)
IC50
72 h (Hs)/IC50
96 h (Pf)
BC194 3.88 3.49 13.32 3,816
BC195 7.15 4.48 72.06 16,084
BC196 6.73 4.40 59.75 13,579
BC197 93.68 76.71 > 100 >1,303
BC218 17.40 25.00 4.61 184
BC219 25.35 18.59 53.63 2,884
BC220 44.36 23.71 95.99 4,048
BC221 36.08 24.19 16.87 697
BC236 57.30 55.21 24.02 435
BC239 8.13 8.05 16.76 2,081
BC240 9.63 17.25 92.26 5,348
BC249 11.06 25.01 17.14 685
BC253 100.60 56.95 > 100 >1,755
Borrelidin 1.24 0.97 345 355
Also see Table S1.
Fig. 2. Library of borrelidin analogs tested on cell-based assays of P. falciparum cultures. The structure of borrelidin is shown with the three substituents
modified in the analog library circled in red. The structural variation of the analogs is color coded red according to the substitutions explored: (i) the nitrile
group was substituted for a carboxylic acid moiety (cyan); (ii) the cyclopentane moiety was substituted for a cyclobutane (yellow) or aliphatic side chain (red);
and (iii) the carboxylic acid group was esterified (pink) or amidated (green). Further, the new ester and amide moieties included a range of smaller substituent
side chains including carboxylate isosteres (gray) or heterocycles (orange), both aromatic and nonaromatic in nature.
Novoa et al. PNAS | Published online December 8, 2014 | E5511
BI
O
CH
EM
IS
TR
Y
PN
A
S
PL
U
S
per day. Interestingly, this was not the most potent analog tested
in in vitro assays, suggesting that compound bioavailability or
other ADME (absorption, distribution, metabolism and excre-
tion) properties affect the activity of borrelidin analogs in vivo.
Finally, it should be noted that all infected mice treated with the
borrelidin derivatives that cleared parasitemia developed immunity
that protected them from reinfection on further parasite challenge
75 d after the primo-infection. At reinfection, microscopic para-
sitemia or any perceptible clinical sign was not detected.
In Vitro Aminoacylation Assays Confirm That BC196 and BC220 Are
More Selective Compared with Borrelidin. To confirm whether the
decrease in cytotoxicity was due to a decreased inhibition of
borrelidin analogs on the human enzyme, we directly measured the
Fig. 3. Antimalarial activity of the library of borrelidin analogs. In vitro antimalarial activities of borrelidin derivatives tested at 100 nM. Borrelidin was
included as positive control. Compounds inhibiting over 80% at 100 nM (13 among the 30 compounds tested) were considered to be active and were selected
for IC50 determination in both P. falciparum iRBC (nanomolar) and HEK293T cultures (micromolar). The fold selectivity comparison of the 13 selected borrelidin
analogs compared with borrelidin is shown. See also Table S1.
Table 3. In vivo i.p. antimalarial activities and curative activity of the five most selective borrelidin derivatives (BC194, BC195, BC196,
BC220, and BC240) against P. yoelii yoelii 17XL-infected mice
Compound
Dose
(mg/kg/d) No. of mice
Average percentage
parasitemia*
Average percentage
suppression
Percentage
survival
Survival days in
fatal cases
Negative control — 5 (×2)† 87.0 ± 2.6 0 0 4.8 ± 0.3
Chloroquine 6 5 2.2 ± 2.4 97.5 ± 2.8 100 —
Borrelidin 0.25 5 (×2)† 1.3 ± 0.3 98.9 ± 0.5 100 —
BC194 0.25 5 71.5 ± 4.3 17.8 ± 4.9 0 5.0 ± 0.1
6 5 9.0 ± 2.0 89.7 ± 2.2 40 8.3 ± 0.3
BC195 0.25 4‡ 87.2 ± 3.0 1.7 ± 2.1 0 4.7 ± 0.7
6 5 41.7 ± 13.3 52.0 ± 15.3 25 6.3 ± 0.3
BC196 0.25 5 75.8 ± 2.6 12.8 ± 3.0 0 5.2 ± 0.2
6 5 4.7 ± 2.0 94.6 ± 2.3 100 —
BC220 0.25 5 3.3 ± 1.2 96.2 ± 1.3 80 9.0 ± 0.1
6 5 0.1 ± 0.1 99.9 ± 0.2 100 —
BC240 6 5 19.1 ± 5.5 78.1 ± 6.3 60 7.5 ± 0.3
*Parasitemia was determined by microscopic examination of Wright’s stained blood films taken on day 4 p.i. Results are presented as the mean value ± SEM.
†A preliminary experiment was performed with borrelidin-treated and negative control mice to calculate the suppression activity and the group size required
(Materials and Methods). Results from the two groups of five are displayed.
‡One mouse from this group was lost during manipulation, and, due to the low suppression activity and the homogeneous results, the experiment was not
repeated.
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ability of the three top-ranked borrelidin analogs (BC194, BC196,
and BC220), based on the in vivo results, to inhibit the amino-
acylation reaction of both P. falciparum and human ThrRS.
P. falciparum encodes a single ThrRS that acts both in the
cytosol and the apicoplast (28). In contrast, human cells encode
two distinct ThrRSs that act separately in the cytosol and the
mitochondria. (Fig. S2A). The degree of conservation of the
active sites of the two human enzymes suggests that both can be
sensitive to borrelidin (Fig. S2 B and C). Nevertheless, the fact
that the human cytosolic ThrRS is expressed at levels 300-fold
higher compared with the mitochondrial ThrRS suggests that the
major target that is being evaluated in cell-based assays in human
cells is the cytosolic ThrRS (Fig. S2A). Therefore, amino-
acylation assays were performed using purified human cytosolic
ThrRS as enzyme source. As expected, our results confirm that
both BC196 and BC220 are more selective than borrelidin and
that the observed decrease in cytotoxicity is likely due to a de-
creased inhibition of human ThrRS (Fig. 4C and Table 4).
Importantly, we also find that there is a clear structure-activity
relationship for the borrelidin analogs (Figs. 2 and 3). The most
selective compounds were found to have either changes in the
native cyclopentane ring that conferred different stereochemical
and rotational constraints on the carboxylic acid group (e.g.,
switch to cyclobutyl, BC194/5/6 series) or had an ester bond
substituent of the carboxylic group (BC220/240). Indeed, all
analogs containing ester bond substitutions (BC219/220/239/240)
not only retained strong antimalarial activity but also showed a
significant decrease in cytotoxicity (more than eightfold) com-
pared with borrelidin (Fig. 3 and Table 2). In contrast, amide
derivatives showed little or no antimalarial activity at the tested
concentrations. Remarkably, this was also true even in those
cases where the unique difference between two given analogs
was exclusively the amide bond in comparison with an ester bond
linkage (e.g., BC220 compared with BC245).
In Silico Analysis Does Not Explain the Selectivity of Borrelidin Analogs.
Previous work identified borrelidin as a noncompetitive inhibitor
with respect to threonine and ATP in E. coli ThrRS (23). Thus,
borrelidin was predicted to bind close to the active site, but
without overlapping the binding site of either ATP or threonine.
Recently, the X-ray structures of borrelidin-bound E. coli and
human ThrRS have been obtained and they reveal that borrelidin
binds to the active site of the enzyme. The structural explanation
for the noncompetitive nature of the inhibitor remains, however,
undetermined.
To understand the structural reasons behind the selectivity of
certain borrelidin analogs, we used in silico docking to predict
their binding modes on both P. falciparum and human ThrRS.
We first built a homology model of P. falciparum ThrRS using
the borrelidin-bound ThrRS structures as templates. We then in
silico docked BC220 and BC196, the two borrelidin derivatives
that showed best in vivo activity and selectivity. As expected,
binding of the borrelidin moiety of the two analogs overlapped
with the binding mode of borrelidin itself (Fig. 4E). However, the
structural differences found in these two compounds cannot
explain the differences in selectivity observed compared with
borrelidin. The high conservation of P. falciparum and human
ThrRS at their borrelidin binding sites led to very small differ-
ences in terms of docking scores (a proxy for binding affinity)
compared with borrelidin (Fig. 4D), and therefore our in silico
Fig. 4. In vitro and in vivo activities of BC196 and BC220. (A) Chemical structure of BC196 and BC220 compared with borrelidin. (B) In vivo mice survival of
P. yoelii-infected mice treated with the selected subset of borrelidin analogs. Percentage of mice survival of P. yoelii-infected mice, measured over 20 d after
drug treatment. Chloroquine (Cq) has been used as positive control (Table 3). (C) Comparison of the inhibitory activity of the aminoacylation reaction cat-
alyzed by human cytosolic ThrRS. (D) Homology model of P. falciparum ThrRS. Residues have been colored by its conservation with the human cytosolic ThrRS:
conserved -same residue- (yellow), not conserved -different residue- (white). Borrelidin is shown in magenta, whereas AMP is shown in cyan. (E) Predicted
binding mode of BC196 (green) and BC220 (cyan), superimposed with the predicted binding mode of borrelidin (magenta) in Homo sapiens. Predicted binding
modes are identical to those found in P. falciparum ThrRS (not shown in figure).
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analysis does not provide an explanation for the selectivity that
we observe. An explanation for this discrepancy is that the dif-
ferences in selectivity are not due to differences in ligand binding
affinity but are instead due to different ADME properties of the
analogs, such as drug permeability, which may make these mol-
ecules more selective despite maintaining a similar binding mode
for ThrRS.
BC220 Is Not Cleaved to Borrelidin by Esterases. The observation
that all borrelidin analogs with ester substitutions show strong
antimalarial activity both in vivo and in vitro, but exhibit higher
Ki values against ThrRS (e.g., BC220) than other analogs, sug-
gests that they may actually be acting as prodrugs. Importantly,
cleavage of the ester linkage of borrelidin derivatives would yield
borrelidin as a result, which is more potent than any of its ana-
logs at inhibiting PfThrRS.
To explore this possibility, we carried out time course experi-
ments with infected red blood cells (RBCs) to determine whether
BC220 was converted to borrelidin in the cultures. We incubated
human RBCs and human RBCs infected with P. falciparum with
borrelidin and BC220. Duplicate samples were recovered at
30 min, 3 h, and 27 h, following the protocol described (Materials
and Methods) for the extraction of metabolites from erythrocytes.
All of the resulting samples were analyzed by HPLC with pho-
todiode array detector (HPLC-PDA) to determine the presence
or absence of borrelidin and BC220. We find that borrelidin
remains stable in the cultures and is not degraded in the course of
the experiment (Fig. 5 and Table S2). Similarly, BC220 remains
stable in all of the samples analyzed (Table S2), and it is not
converted to borrelidin at least within the detection limits of our
equipment. These results suggest that the biological effect of
BC220 upon P. falciparum-infected RBCs in culture is not due to
its conversion to borrelidin by RBC or plasmodial esterases
(Fig. S3).
Discussion
Resistance of malaria parasites to available drugs continues to
grow, limiting our ability to control this serious disease. Although
our understanding of the parasite’s biology has increased now
that the sequence of the Plasmodium genome is available (43),
few new drug targets or classes of drugs have been validated (44,
45), and current therapies seem to be insufficient for malaria
elimination (45–47). Major antimalarial efforts during the last
few years include strategies as diverse as the use of combination
therapy; the development of analogs of existing agents; the dis-
covery of natural products inhibitors; compound reprofiling; the
evaluation of drug resistance reversers; and the consideration of
new chemotherapeutic agents (30, 31, 44, 48, 49).
Among the latter, several high-throughput in vitro screening
campaigns against P. falciparum-infected RBCs (iRBCs) have
been published. A library of two million compounds from
GlaxoSmithKline’s chemical library was screened against P. fal-
ciparum cultures (50). Of these, 13,500 inhibited parasite growth
and more than 8,000 also showed potent activity against a mul-
tidrug resistant strain. The public availability of this large set of
potent and drug-like antiplasmodial structures provides reason-
able staring points for further drug development. In a similar
fashion, chemical genetic approaches to assay more than 300,000
chemicals (51) and more than 12,000 natural products (52)
against P. falciparum iRBCs have been performed. Although
these approaches are extremely powerful to identify novel potent
antimalarial scaffolds, the lack of knowledge of their respective
molecular targets hinders hit-to-lead optimization during the
drug development process.
Aminoacyl-tRNA synthetases are essential and druggable
targets whose activity can be easily measured through in vitro
aminoacylation assays (13, 15). Although underexploited for
many years, recent work has shown that plasmodial ARS are not
only druggable enzymes (17, 18) but also that selective inhibition
of these enzymes versus their human homologs is feasible (16).
In this work, we evaluated and tested a series of known ARS
inhibitors on P. falciparum cell cultures and explored their ability
to inhibit parasite replication in vitro. Among these, borrelidin is
the most potent antimalarial inhibitor (IC50 = 0.97 nM). How-
ever, borrelidin is not selective enough for clinical applications
(21). For this reason we decided to test borrelidin analogs to
identify more selective inhibitors.
Recently, a series of borrelidin derivatives was explored
for their ability to inhibit cell cultures of P. falciparum iRBCs
(30). Borrelidin analogs were produced semisynthetically by (i)
diacetylation at C3 and C11; (ii) several types of modifications
at C22 (on the cyclopentane ring); and (iii) reduction of the
diene functionality at C12–C15. The study found that analogs
with modifications at the carboxyl group of C22 showed lower
in vitro cytotoxicity, which is in accordance with our results.
However, they did not test the inhibitory activity against the
aminoacylation reactions catalyzed by PfThrRS and HsThrRS or
ascertain whether the synthesized compounds possessed in vivo
activity. Here we show not only that some borrelidin analogs
have greater than 10-fold selectivity over borrelidin, but also that
they can retain strong in vivo activity. Indeed, BC220 shows strong
in vivo activity with 100% mice survival, a parasite clearance
comparable to chloroquine and improved immunological pro-
file on reinfection (20).
Despite its increased Ki, BC220 clears malaria from P. yoelii-
infected mice with 100% mice survival. Some drugs, once ad-
ministered to cell cultures or whole organisms, are converted to
their active form through normal metabolic processes. For ex-
ample, salicin is cleaved by esterases to release salicylic acid, the
active molecule of aspirin (53). In this line of thought, we first
hypothesized that ester borrelidin derivatives, such as BC220, may
actually be cleaved by esterases, releasing borrelidin. However, we
have shown that BC220 is stable in RBC cultures and that it is not
converted into borrelidin. This observation indicates that BC220 is
a promising lead antimalarial compound that combines activity,
safety, and chemical stability in vitro. Another potential explana-
tion for our results with ester borrelidin derivatives is that these
compounds may offer increased selectivity due to better perme-
ability in infected erythrocytes. Malaria parasites have been shown
to increase erythrocyte permeability to ions, organic solutes, and
antimalarial drugs through new permeation pathways that are
associated to P. falciparum infection (54–57). Further work is
needed to determine the role of permeability differences in the
selectivity of borrelidin analogs.
Although it is a formal possibility, existing data indicate that
nonspecific adsorption of borrelidin to supernatant protein is not
a factor in our data. The Ki of borrelidin for human ThrRS is
5 nM, whereas the Ki for secondary targets such as splicing factor
FBP21 or CDKs, are more than 1000-fold higher, approximately
of 10 μM (26, 58). Moreover, borrelidin exhibits comparable
potencies in the HUVEC (human umbilical vein endothelial
cells) tube formation and chicken chorionic allantoic membrane
Table 4. In vitro inhibition of the aminoacylation reaction
catalyzed by P. falciparum and human ThrRS
Compound
Pf ThrRS
[Ki (nM)]
Hs ThrRS
[Ki (nM)]
Selectivity compared
with borrelidin (fold)
BC-194 120 4.09* 0.87
BC-196 440 208.20 12.17
BC-220 4,750 No inhibition† Not applicable
Borrelidin 140 5.44 1.00
*Data from Williams et al. (26).
†No inhibition found at the maximal concentration tested (10 μM).
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models, the concentration and composition of extracellular
proteins of which is vastly different (26). It has also been shown
that a point mutant in the active site of human ThrRS fully blocks
the antiangiogenesis effects of the borrelidin analog BC194,
whereas the corresponding substitution in E. coli ThrRS similarly
confers a 4-log increase in resistance to borrelidin (23, 26). Thus,
previously published data demonstrate that borrelidin and some
of its analogs display comparable inhibitory properties against
ThrRS despite being tested under very different assay conditions.
All of these argue against off target effects being the basis of the
selectivity differences reported here.
Our results show that borrelidin can be used as a scaffold for
antimalarial drug design and validate threonyl-tRNA synthetase
as a druggable antimalarial drug target. We further show that
two borrelidin analogs, BC196 and BC220, have antimalarial
activity both in vitro and in vivo. Importantly, their increased
selectivity toward P. falciparum iRBCs is comparable to that
found in commercially available drugs (e.g., mupirocin, 8,000-
fold selectivity), and in the case of BC220, its in vivo potency and
parasitemia clearance is similar to chloroquine. Moreover, BC220
does not inhibit human cytosolic ThrRS, within the range of con-
centrations tested, and a 4,000-fold lower concentration of this
compound is required to kill P. falciparum compared with human
cells in in vitro culture assays. We believe that these encouraging
results, combined with the recently published structure of borreli-
din-bound ThrRS, provide useful guidelines for future structure-
based drug design efforts to identify a new generation of borrelidin
analogs with further increased selectivity and potency.
Materials and Methods
Reagents. Natural product aminoacyl-tRNA synthetase inhibitors were pur-
chased from the following companies: mupirocin (GlaxoSmithKline), borrelidin
(Fluorochem), cispentacin (Acros organics), and thialysine (Sigma).
AN2729 was a gift from ANACOR. The library of borrelidin analogs was
provided by Biotica Technology and produced using published methods
(24, 42). Sulfamoyl adenosine analogs were a kind gift from Magali
Frugier (CNRS).
IC50 Determinations. IC50 determinations were performed with synchronous
3D7-A parasite cultures. Parasites were cultured in B+ human erythrocytes
under standard conditions, with RPMI 1640-based medium supplemented
with Albumax II and no human serum. To calculate the IC50 of the most
active compounds, parasitemias were determined by FACS using Syto-11 to
discriminate parasitized from nonparasitized RBCs (59). Each sample was
diluted 1:100 in PBS, and 0.5 mM Syto-11 in DMSO was added to a final
concentration of 0.5 μM. Samples were excited at 488 nm and analyzed
using an FC500 flow cytometer. Data analysis was performed with the
software package Prism 5.
Cell-Based Drug Inhibition Assays. Initial screens to test the activity of com-
pounds against cultured parasites were performed using the lactate de-
hydrogenase (LDH) activity assay. To perform the assay 20 μL of sorbitol-
synchronized infected erythrocytes (3% hematocrit) in each well of a 96-well
plate were mixed with 100 μL of Malstat reagent, 10 μL of 2 mg/mL of
nitroblue tetrazolium and 10 μL of 0.2 μg/mL phenylethyl sulfate. After
30min of incubation in the dark the reaction was stopped by adding 100 μL
of 5% acetic acid to each well. Absorbance at 590nm was measured on
a plate reader to quantify the LDH activity, which is proportional to the
parasitemia. Smears were also prepared for each drug assay to visually
confirm the results based on absorbance results (microscopy counting of
Giemmsa-stained smears). For each compound tested, parasite LDH activity
was measured both at 48 and 96 h to determine whether the compound
exerts a delayed death. Inhibitory compounds were applied to tightly syn-
chronized cells and analyzed by comparing growth between treated and
control cultures. A drug was considered to cause delayed death if it met the
two following conditions: (i) there was no measurable growth inhibition
after 48 h of treatment at drug concentrations 10-fold higher than those
needed to inhibit 50% of parasite growth at 96 h; and (ii) parasite growth
inhibition was insensitive to the presence or absence of drug during the
second asexual cycle (31).
Cytotoxicity Assays on Human Cells. Cytoxicity was measured using the Cell
Profileration assay WST-1 (Roche) on HEK293T cells. Cells were cultured in
a 96-well microplate and incubated for 2–4 h with WST-1. During this in-
cubation period, viable cells convert WST-1 to a soluble formazan salt, which
was then quantified at 450 nm with an ELISA plate reader.
Enzyme Preparation. The plasmid (pET28a hctThrRS) encodingN-terminal His6-
tagged human ThrRS was a gift from Dieter Soll (Yale University, New
Haven, CT) and used to transform E. coli Rossetta 2(DE3) pLysS competent
cells (EMD). Cells were cultured in Terrific Broth supplemented with 100
mg/mL kanamycin and 100 mg/mL chloramphenicol at 37 °C and grown to a cell
density of A600 = 0.6. ThrRS expression was induced by overnight incubation
with 1 mM isopropyl 1-thio-β-D-galactoside (IPTG) at 15 °C. The bacterial
pellet was lysed by sonication in buffer A (20 mM potassium phosphate
buffer, pH 8.0, 100 mM KCl, 35 mM imidazole, and 5 mM β-mercaptoetha-
nol) and cleared by centrifugation at 17,000 × g for 30 min. Nucleic acids
were precipitated by the addition of Protamine sulfate to a final concen-
tration of 0.3%, followed by additional centrifugation. The supernatant was
loaded onto a HisTrap FF column (GE Healthcare) equilibrated with buffer A
and eluted by an imidazole gradient of 35–250 mM over 20 column volumes.
ThrRS containing fractions were identified by SDS/PAGE and GelCode Blue
(Thermo Scientific), pooled, and dialyzed into buffer B (100 mM potassium
phosphate buffer, pH 6.8, and 5 mM β-mercaptoethanol). The sample was
loaded onto a CHT-Tricorn hydroxyapatite column and eluted over 20 col-
umn volumes by a gradient of buffer B to buffer C (500 mM potassium
phosphate, pH 8.0, and 5 mM β-mercaptoethanol). ThrRS containing frac-
tions were determined by SDS/PAGE, dialyzed into buffer D [20 mM Hepes,
pH 8.0, 100 mM KCl, 5 mM β-mercaptoethanol, and 40% (vol/vol) glycerol],
and stored at −20 °C.
P. falciparum extracts for aminoacylation assays were prepared by hy-
potonic lysis of saponin-extracted parasites. In brief, parasite cultures were
pelleted by centrifugation and resuspended in two pellet volumes of 0.15%
saponin (Sigma) in PBS buffer (for a 0.1% final concentration of saponin).
After incubating for 5 min in ice to lyse RBC membranes, intact parasites
were recovered by centrifugation and washed twice with PBS. Parasites
pellets were resuspended in hypotonic lysis buffer consisting of 20 mM
Hepes, pH = 7.8, 10 mM KCl, 1 mM EDTA, and a protease inhibitors mixture
(Roche). After incubating for 10 min in ice, extracts were centrifuged, and
the supernatant was used for aminoacylation assays.
Fig. 5. HPLC-PDA analysis of borrelidin and BC220 stability in P. falciparum-infected RBC cultures. HPLC-PDA traces of extractedmetabolites from P. falciparum-infected
RBC treated with BC220 (cyan, magenta, yellow) and borrelidin (blue, green, brown), respectively. The traces do not vary as incubation time increases. The peak cor-
responding to BC220 is highlighted with a green asterisk, and the peak corresponding to borrelidin is highlighted with a red asterisk. See also Table S2 and Fig. S3.
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tRNAThr Preparation. E. coli XL-1 Blue (Stratagene) cells expressing the plas-
mid pUC18hcttRNAThr-TGT, coding for human tRNAThr, were cultured in
Luria-Bertani (LB) broth supplemented with 100 mg/mL ampicillin at 37 °C to
a cell density of A280 = 0.5. Expression of tRNAThr was induced with 1 mM
IPTG for 14 h. Bacterial pellets were resuspended in 20 mM Tris, pH 7.5,
20 mM MgCl2, and 10 mM β-mercaptoethanol and extracted with water
saturated phenol (pH = 4.8). The aqueous fractions were ethanol pre-
cipitated, resuspended in 10 mM Hepes and 50% formamide, and resolved
using 8 M urea/10% polyacrylamide gel electrophoresis. The tRNA was
identified by UV shadowing, electroeluted, and ethanol precipitated. The
tRNA pellet was resuspended in 10 mM Hepes and stored at −20 °C. The
active concentration of tRNAThr was determined by plateau charging assay.
Aminoacylation Assays and Ki Determination. The apparent inhibition con-
stant ðKappi Þ of the various inhibitors for ThrRS was determined using mod-
ifications to previously described steady-state aminoacylation procedures
(23). Reaction mixtures consisted of 20 mM Hepes, pH 8.0, 100 mM KCl,
10 mM MgCl2, 5 mM β-mercaptoethanol, 20 μM [14C]-threonine, 180 μM
unlabeled threonine, 7.5 μM tRNAThr, 40 nM ThrRS, and various concen-
trations of borrelidin, BC196, or BC220. Reactions were incubated for at least
10 min on ice to allow for the slow binding of inhibitors and initiated with
the addition of 2 mM ATP. Aliquots were taken at varying time points and
spotted onto Whatmann 3MM paper filters presoaked in 5% trichloroacetic
acid (TCA). On reaction completion, the filters were washed three times in
excess TCA and once in 95% ethanol and dried under a heating lamp. The
formation of Thr-tRNAThr was detected by scintillation counter, and the activity
was determined by linear regression of threonyl-tRNAThr formed per active site
per unit time. Values for Kappi were obtained by plotting fractional velocity as
a function of inhibitor concentration and fitting the data to Morrison’s quadratic
equation for tight binding inhibitors (60) using GraphPad Prism software
vi
v0
= 1−
½ET + ½IT +Ki −
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ½ET + ½IT +Ki
2 − 4½ET ½IT
q
2½ET
,
where [E]T is the concentration of total active enzyme in the reaction, [I]T is
the total inhibitor concentration, and Ki the apparent inhibition constant.
Preclinical Treatments on a P. yoelii in Vivo Model of Lethal Malaria. The in vivo
study was carried out according to standard protocol following the 4-d
suppressive test (61) implemented as previously described (20, 62). Seventy
inbred BALB/cAnNHsd pathogen-free female mice, aged 7 wk and weighting
17–20 g (average, 18.34 g; Harlan Laboratories) were housed at random in
50 × 25-cm airy racks containing 10 labeled animals each. Animals were kept
under constant standard conditions of light (12:12-h light:dark cycles), tem-
perature (22–24 °C), humidity (∼50%), ad libitum diet (2018 Teklad Global
18% Protein Rodent Diet; Harlan Laboratories), and bedding (Lignocel;
Rettenmaier & Sohne) at the Animal House of Universidad Complutense de
Madrid. The rodent malaria parasite P. yoelii yoelii 17XL was kindly provided
by Virgilio Do Rosario (Universidade Nova de Lisboa, Lisboa, Portugal) and
stored in liquid nitrogen after serial blood passages in mice.
For the present study with borrelidin analogs, to follow the 3Rs principles
(63), we used a 99% value of suppression activity as previously obtained with
borrelidin against P. yoelii yoelii 17XL (20) to calculate the minimal number
of animals (n = 5) to detect a minimum suppression activity of 25%with 80%
of statistical power (b = 0.2) and 95% confidence level (a = 0.05). BALB/
cAnNHsd mice were infected i.p. on day 0 with 2 × 107 P. yoelii yoelii 17XL-
infected red blood cells between 10:00 and 12:00 AM, using a 30-G 1/2-in.
needle at ∼15° angle in the lower quadrant of the abdomen off midline.
P. yoelii 17XL-infected mice were selected at random for treatment with
borrelidin (0.25 mg/kg), borrelidin analogs (0.25 or 6 mg/kg) and chloro-
quine (6 mg/kg). The tested drugs were prepared at appropriate doses in
a final volume of 100 mL of aqueous vehicle containing 7% Tween-80 and
3% ethanol as previously described (64). Control animals, also selected at
random, received aqueous vehicle (100 mL) by the same route. Four-day
treatments were carried out at the animal room, starting 2 h after infection.
Ad libitum drinking water during the experiment contained 0.05% of
p-aminobenzoic acid, which is essential for the parasite growth and there-
fore for the infection establishment (65). Parasitemia was monitored daily
(between 9:00 and 10:00 AM) in each mouse by performing Wright’s staining
on thin tail blood smears. The number of dead mice was recorded every 12 h
from all of the treatment groups to determine the average survival time.
In Silico Analysis of the Selectivity of Borrelidin Analogs. The primary sequence
of P. falciparum ThrRS was downloaded from the Uniprot database (www.
uniprot.org). The 9v12 version of MODELER (66) was used to create the
homology model, using as templates borrelidin-bound human and E. coli
ThrRS structures. The model was manually refined, including corrections of
the alignment using the PSI-PRED (67) secondary structure predictions as
guideline, followed by a new rebuilding of the model. The final model was
analyzed using ProSA (68) and then validated using PROCHECK (69). Both
P. falciparum ThrRS homology model and human ThrRS were structurally
superimposed to the E. coli ThrRS structure using STAMP (70). Borrelidin,
BC220, and BC196 were docked against P. falciparum and human ThrRS using
the software Glide v. 5.0 (71). The ligands were prepared with the LigPrep
facility of MAESTRO (Schrödinger LLC), whereas the setup of the protein was
done with the Protein Preparation Wizard facility. Schrödinger’s GlideScore
scoring function was used to score and rank the predicted docking poses.
HPLC-PDA Analysis of Borrelidin and BC220 in Erythrocyte Cultures. The sta-
bility of borrelidin and BC220 in cultures of RBCs alone or infected with
synchonized P. falciparum (>6% parasitemia) was tested after 30 min, 3 h,
and 27 h of incubation with the drugs. Cultures at the late trophozoite stage
were collected after being treated with the drugs for the stated times and
prepared for HPLC-PDA analysis using the protocol for liquid-liquid extrac-
tion of metabolites from erythrocytes developed by Agilent Technologies
(www.agilent.com/chem/metabolomics.)
Borrelidin and BC220 detection was performed using an HPLC-PDA system
composed of an Alliance 2695 (Waters) with auto sampler, column oven set at
30 °C, and a photodiode array detector 2996. Empower 2 software was used for
instrument control and acquisition data, and an Xbridge C18 column was used
for the separation (Waters). The elution system was composed by A:H2O:HCCOH
[99.9:0.1 (vol/vol)] and B: CH3CN [99.9:0.1 (vol/vol)]. Samples were eluted with
a linear gradient of 5%B to 100%B in 4.5 min at a flow rate of 1.6 mL/min.
Injection volumes were 10 μL and compounds were detected at 257 nm.
Metabolite Extraction from RBC Cultures After Drug Incubation. Synchronized
cultures of P. falciparum infected and noninfected RBCs were treated with no
inhibitor, BC220, or borrelidin. To incubate the parasites the exact amount of
time (27 h), 20 μL of 1 mM of water, BC220, or borrelidin was added to 2mL of
cell culture at different time points. For each of the three conditions (water/
BC220/borrelidin), drugs were added at t = 0, 24, and 26.5 h, corresponding to
incubation times of t = 27 h, 3 h, and 30 min, respectively, both with infected
and noninfected RBC cultures. At t = 27 h, samples were collected, and
metabolites were extracted using the Metabolite Extraction Protocol for
Metabolomics Studies of Erythrocytes (Agilent Technologies). Briefly, 0.5 mL of
the erythrocyte samples was centrifuged and resuspended in water, incubated
in a water bath at 37 °C for 0.5 min, and resuspended in −20 °C methanol; 0.45
mL of chloroform and 0.15 mL of ice cold water were added to each tube.
After centrifugation, the top and bottom phases were separated, vacuum
dried, and independently analyzed by HPLC-PDA. Duplicates for each sample,
condition, and time point were produced and analyzed (Table S2).
Ethics Statement. All animal care and experimental procedures carried out at
Complutense University of Madrid complied with Spanish (R.D. 32/2007) and
European Union legislation (2010/63/CE), were approved by the Animal Experi-
mentation Committee of this institution, and are reported following the ARRIVE
(Animal Research: Reporting of In Vivo Experiments) guidelines (62). The number
of animals was calculated using Statgraphics Centurion 16.1.18 software (Stat-
point Technologies) to provide about 80% of statistical power with 95% confi-
dence level, always following the 3Rs principles.
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